Over the last 17years, clinical trials conducted worldwide have demonstrated the efficacy of
arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia (APL) …

Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As (III)
and As (V). As (III), in particular, reacts with closely spaced protein thiols, forming stable …

We analyzed prognostic factors of response, response duration, and possible impact on
survival of epoetin α, epoetin β, or darbepoetin α (DAR) with or without granulocyte colony …

The myelodysplastic syndromes (MDSs) are common, acquired, clinically challenging
hematologic conditions that are characterized by bone marrow failure and a risk of …

Arsenic trioxide has shown great promise in the treatment of patients with relapsed or
refractory acute promyelocytic leukemia (APL). In clinical trials, arsenic trioxide induces …

Starting in ancient China and Greece, arsenic-containing compounds have been used in the
treatment of disease for over 3000 years. They were used for a variety of diseases in the …

We report the results of a screen for genetic association with urinary arsenic metabolite
levels in three arsenic metabolism candidate genes, PNP, GSTO, and CYT19, in 135 arsenic …

Myelodysplastic syndromes (MDS) are a set of oligoclonal disorders of hematopoietic stem
cells characterized by ineffective hematopoiesis that manifest clinically as anemia …

The ecotropic viral integration site 1 (EVI1) gene was identified almost 20 years ago as the
integration site of an ecotropic retrovirus leading to murine myeloid leukemia. Since its …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis
presenting with peripheral cytopenias in combination with a hyperplastic bone marrow and …